Structure Therapeutics, Inc. (GPCR)
36.58
+0.56
(+1.55%)
USD |
NASDAQ |
Sep 25, 11:41
Structure Therapeutics Research and Development Expense (Quarterly) : 100.22M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 100.22M |
| March 31, 2026 | 66.71M |
| December 31, 2025 | 68.99M |
| September 30, 2025 | 59.07M |
| June 30, 2025 | 54.90M |
| March 31, 2025 | 42.93M |
| December 31, 2024 | 33.37M |
| September 30, 2024 | 32.87M |
| June 30, 2024 | 22.02M |
| Date | Value |
|---|---|
| March 31, 2024 | 20.65M |
| December 31, 2023 | 20.18M |
| September 30, 2023 | 17.52M |
| June 30, 2023 | 19.20M |
| March 31, 2023 | 13.11M |
| December 31, 2022 | 8.346M |
| June 30, 2022 | 10.13M |
| March 31, 2022 | 8.504M |
| December 31, 2021 | 9.926M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.819B |
| Novo Nordisk A/S | 1.783B |
| Pfizer Inc. | 2.746B |
| Johnson & Johnson | 3.603B |
| Merck & Co., Inc. | 9.229B |